1/26
Looks like no tags are added yet.
Acute Kidney Injury (AKI)
Rapid decline in filtration/clearance across all three buckets requiring acute renal dose adjustments until kidney function recovers:
Pre-Renal
Volume depletion (GI losses, hemorrhage), decreased effective circulatory volume (heart failure exacerbation, cirrhosis with ascites), or functional hemodynamic shifts (afferent/efferent arteriolar tone changes).
Intrinsic:
ATN (#1 most common; ischemia/sepsis or nephrotoxins), AIN (#2 most common; NSAIDs, beta-lactams), vascular (< 5%), and glomerular (< 5%).
Post-Renal:
Outflow obstruction (sharp drop in urine output + markedly elevated SCr; e.g., acyclovir, methotrexate, tumor lysis syndrome)
Chronic Kidney Disease (CKD
Multifactorial progressive decline in clearance due to loss of nephron mass, glomerular capillary hypertension/hypertrophy (once initial afferent prostaglandin vasodilation and efferent Ang II vasoconstriction compensation fails), and albuminuria (enlarged glomerular pores altering clearance).
Absorption / Bioavailability (A):
Essentially unchanged by CKD itself (though CKD Stages 3–5 exhibit decreased gastric motility and decreased gastric acidity from chronic inflammation, which can alter GI/hepatic non-renal metabolism and drug transport).
4 Downstream PK Consequences of Increased
Decreased peak concentrations (lower serum concentration immediately post-dose)
Increased half-life (t1/2) (less drug in serum available for renal/hepatic elimination)
Delayed time to steady state
Increased risk of elevated trough concentrations if dosed at standard intervals
Two Primary Adjustment Strategies:
Decrease the dose
Increase (extend) the dosing interval
When to Adjust:
Generally required when a drug (or an active metabolite, such as morphine or codeine) is >= 30% cleared by the kidney.
Big Tough Alligators Prefer Dainty Dishes")
B — Beta-Lactams & Antimicrobials:B — Beta-Lactams & Antimicrobials:
T — Therapeutic Drug Monitoring (TDM):
A — Anticoagulants & Antiarrhythmics:
P — Pain Management
D — Diabetes Agents:
D — Digoxin:
B — Beta-Lactams & Antimicrobials:B — Beta-Lactams & Antimicrobials:
Most antibiotics require renal dose adjustments (e.g., ampicillin-sulbactam, cefepime, meropenem, levofloxacin, TMP-SMX).
Antibiotic Exceptions — NO Renal Dose Adjustment Needed (MEMORIZE):
Ceftriaxone (only cephalosporin/beta-lactam underlined exception)
Azithromycin
Doxycycline
Moxifloxacin
Linezolid
Rifampin (plus nafcillin on slide)
T — Therapeutic Drug Monitoring (TDM):
Vancomycin, Gentamicin (aminoglycosides).
A — Anticoagulants & Antiarrhythmics:
Anticoagulants: LMWH (enoxaparin) and DOACs (apixaban, rivaroxaban, dabigatran, edoxaban).
Antiarrhythmics: Dofetilide, Sotalol (note: amiodarone does NOT require renal adjustment).
P — Pain Management
Morphine (avoid in CrCl < 30 / HD due to accumulation of renally cleared active metabolites causing respiratory depression/neurotoxicity), gabapentin (plus meperidine, pregabalin).
D — Diabetes Agents:
Metformin (reduce max dose to 500 mg BID at eGFR 30–44; discontinue at eGFR < 30) and sulfonylureas (hypoglycemia risk).
Allopurinol Pearl
Only requires renal dose adjustment when initiating therapy; once established on a maintenance dose, do not reduce it solely for declining CrCl.
Rosuvastatin Pearll
Hydrophilic statin (> 30% renal clearance) requiring dose reduction to max 10 mg daily when CrCl < 30 mL/min (atorvastatin requires no renal adjustment)
Enoxaparin (Lovenox) 1 mg/kg SQ BID
CrCl < 30 mL/min: 1 mg/kg SQ once daily (q24h)
Apixaban (Eliquis) 5 mg PO BID
Meets >= 2 of 3 criteria (Age >= 80 yrs, Weight <= 60 kg, SCr >= 1.5 mg/dL): 2.5 mg PO BID
Rivaroxaban (Xarelto)
20 mg PO daily CrCl 15–50 mL/min: 15 mg PO daily (Note: Avoid if CrCl < 30 for DVT/PE)
Dabigatran (Pradaxa) 150 mg PO BID
CrCl 15–30 mL/min: 75 mg PO BID
Edoxaban (Savaysa) 60 mg PO daily
CrCl 15–50 mL/min OR Weight <= 60 kg: 30 mg PO daily
General Rule:
Always calculate Cockcroft-Gault CrCl and consult Lexicomp/Micromedex/package inserts; check serum drug levels for narrow therapeutic index medications (e.g., vancomycin, gentamicin) and administer supplemental doses post-HD when indicated.
Hemodialysis (HD)
Clearance depends on drug properties, dialyzer membrane/filter, and session parameters.
Peritoneal Dialysis (PD)
Targets urea clearance of ~10 mL/min with minimal effect on drug clearance -> if specific PD guidance is unavailable, use dosing recommendations for an estimated CrCl of 10–15 mL/min.
Continuous Renal Replacement Therapy (CRRT)
Limited but growing evidence -> general rule of thumb is to assume an estimated CrCl of ~30 mL/min (clears drugs with larger Vd and predominantly renal clearance more extensively over 24 hours than intermittent HD)
Medications LESS Likely to Be Removed by HD / PD:
Increased (large) molecular weight
Highly protein-bound
Increased (large) volume of distribution (Vd) (sequestered in tissues rather than serum)
Ionized drugs